Thank-you for the links, I hadn't seen those before. The first 9 candidates have either fast track or breakthrough status, but not both and there are none with both, which isn't surprising as only Ocaliva and IMM124E are breakthrough, Ocaliva is clearly suspect so can't sustain the number 1 position.
The nashbiotechs own analysis of Immuron:
http://www.nashbiotechs.com/nash-biotech-analysis/point-of-view/immuron---interim-analysis.html
needs updating as they describe IMM124E as "safe but has no impact on nothing"
There is so much more at stake with Nash treatment -money wise- it looks as though desperation is causing corruption of the Science in more than one player.
I own shares and want to see myself benefit finically-of course- but with these biotech breakthroughs its all about patent and protecting intellectual property ahead of sharing to find the best cure fast for very sick people. Sorry that sounds smart arsey, I'm still hoping for a hundred bagger!
